These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9990650)

  • 61. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function.
    Greven J; Gabriëls G
    Arzneimittelforschung; 2000 Nov; 50(11):973-9. PubMed ID: 11148863
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats.
    Toblli J; Cao G; Rivas C; Munoz M; Giani J; Dominici F; Angerosa M
    J Hypertens; 2010 May; 28(5):1007-19. PubMed ID: 20411618
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Acute hemodynamic effects of moderate doses of nebivolol versus metoprolol in patients with systolic heart failure.
    Triposkiadis F; Giamouzis G; Kelepeshis G; Sitafidis G; Skoularigis J; Demopoulos V
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):71-7. PubMed ID: 17323786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Metabolic effects and safety profile of nebivolol.
    Pessina AC
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S33-5. PubMed ID: 11811391
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Comparison of effects of nebivolol and atenolol on P-wave dispersion in patients with hypertension].
    Tuncer M; Fettser DV; Gunes Y; Batyraliev TA; Guntekin U; Gumrukchuoglu KhA; Eryonucu B; Guler N; Sidorenko BA
    Kardiologiia; 2008; 48(4):42-5. PubMed ID: 18447840
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
    Toblli JE; Cao G; Casas G; Mazza ON
    Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nebivolol for heart failure in the elderly.
    Tavazzi L
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):423-33. PubMed ID: 17489667
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers.
    Pauwels PJ; Gommeren W; Van Lommen G; Janssen PA; Leysen JE
    Mol Pharmacol; 1988 Dec; 34(6):843-51. PubMed ID: 2462161
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute effects of third generation β-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats.
    Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
    Hypertens Res; 2013 Apr; 36(4):349-55. PubMed ID: 23364340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].
    Buval'tsev VI; Spasskaia MB; Nebieridze DV; Metel'skaia VA; Guseva OI
    Klin Med (Mosk); 2003; 81(7):51-5. PubMed ID: 12934313
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Stereochemical comparison of nebivolol with other beta-blockers.
    Siebert CD; Hänsicke A; Nagel T
    Chirality; 2008 Feb; 20(2):103-9. PubMed ID: 18072266
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacological augmentation of endothelium-derived nitric oxide synthesis.
    Bakris GL
    J Manag Care Pharm; 2007 Jun; 13(5 Suppl):S9-12. PubMed ID: 17605505
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Beta-adrenoceptor-mediated cAMP accumulation in cardiac cells: effects of nebivolol.
    Pauwels PJ; Leysen JE; Janssen PA
    Eur J Pharmacol; 1989 Dec; 172(6):471-9. PubMed ID: 2575531
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.
    Maack C; Tyroller S; Schnabel P; Cremers B; Dabew E; Südkamp M; Böhm M
    Br J Pharmacol; 2001 Apr; 132(8):1817-26. PubMed ID: 11309254
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nebivolol: a new antihypertensive agent.
    Gray CL; Ndefo UA
    Am J Health Syst Pharm; 2008 Jun; 65(12):1125-33. PubMed ID: 18541682
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial.
    Van Nueten L; Lacourcière Y; Vyssoulis G; Korlipara K; Marcadet DM; Dupont AG; Robertson JI
    Am J Ther; 1998 Jul; 5(4):237-43. PubMed ID: 10099065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.